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Induction chemotherapy followed by concurrent 
chemoradiotherapy (CCRT) versus CCRT alone for unresectable 
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Background: We conducted a prospective randomized phase III trial 
comparing induction chemotherapy followed by concurrent chemora-
diotherapy (CCRT) versus immediate CCRT to evaluate whether the 
addition of induction chemotherapy would result in improved survival. 
Methods: Patients with unresectable stage III NSCLC, ECOG PS 0-1, 
and weight loss up to 10% were eligible. They were randomized to 
receive either induction chemotherapy followed by CCRT (arm A) or 
immediate CCRT (arm B) after stratiﬁcation for stage (T4N0-2, T1-
3N3, T4N3, and stage IIIA), histology (squamous vs non-squamous), 
and SCLN positivity. Induction chemotherapy consisted of two cycles 
of gemcitabine (1000mg/m2 D1, D8) and cisplatin (70mg/m2 D1) q 
21days. Chemotherapy during CCRT consisted of 6 cycles of weekly 
paclitaxel (50mg/m2) and cisplatin (20mg/m2). Radiation therapy per-
formed with hypofractionated scheme (2.2Gy/fraction, once a day) and 
total dose was 66Gy. Irradiated volume encompassed gross tumor plus 
1.0cm margin. 
Results: Between March 2003 and June 2006, 134 patients were 
enrolled. 92% of patients were male and 60% were age 60 or older. 
Objective tumor response was obtained in 38% after induction chemo-
therapy. Response rates after completion of CCRT were 72% (95% CI, 
61%-83%) on arm A and 79% (95% CI, 69%-89%) on arm B. Grade 
3/4 toxicities during induction chemotherapy consisted mainly of neu-
tropenia (11%/3%). During CCRT, grade 3/4 neutropenia was noted in 
8%/5% (arm A) versus in 8%/0% (arm B), grade 3 anemia was 8% vs 
0%, grade 3 thrombocytopenia 5% vs 0%, and grade 3 esophagitis 16% 
vs 16%. At median follow-up of 28 months, median survival was 12.6 
months (95% CI, 8.6-16.7 months) on arm A versus 18.2 months (95% 
CI, 11.7-24.8 months) on arm B (P=0.18). Two year survival estimates 
was 25% (15%-35%) and 43% (31%-55%), respectively. Median pro-
gression free survival was 7.5 months (95% CI, 5.6-9.4 months) on arm 
A and 11.6 months (95% CI, 9.6-13.6 months) on arm B (P=0.04). 
Conclusions: The addition of induction chemotherapy to CCRT failed 
to increase the survival of unresectable stage III NSCLC over imme-
diate CCRT. Moreover, the progression free survival was inferior to 
immediate CCRT.
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Background: The survival of patients after a complete resection of 
stage III-N2 NSCLC may be improved by PORT. LungART is a phase 
III trial where such patients are randomized to between PORT and no 
PORT, irrespective of the use of chemotherapy. LungArt target volumes 
are based upon the post-surgical ﬁndings in each patient, and on the 
surgical literature. As a previous meta-analysis has reported an increase 
in mortality after PORT, quality assurance for target deﬁnitions will 
be monitored. An international ‘dummy run’ was performed to study 
routine PORT volumes and evaluate the LungART protocol.
Methods: A CD-rom based contouring program containing the plan-
ning CT scans of 2 patients (post-lobectomy and pneumonectomy, 
respectively) were mailed to 17 thoracic radiation oncologists from 4 
continents. Relevant clinical, radiological and pathological reports were 
provided in order to allow clinicans to contour their ‘routine’ clinical 
target volumes (CTV). Contours were saved onto a CD-rom and mailed 
to the study center. The LungART protocol was then provided and ‘pro-
tocol’ CTVs were generated. Contours of each case were transferred 
to a template CT dataset of that patient, and nodal CTVs were jointly 
generated by two clinicians using published deﬁnitions. An optimised 
treatment plan was generated for all CTV’s.
Results: For each case, a total of 10 routine CTVs were received. Both 
routine and protocol CTVs were provided for each case by 6 clinicians. 
The routine CTVs varied up to 3-fold between clinicians and this was 
signiﬁcantly decreased by use of the protocol (F test, p=0.00003 and 
p=0.00002 for cases 1 and 2, respectively). The 2 CTV’s generated for 
case I by each observer (same color) is indicated on Figure 1. Coverage 
of nodal stations 2R and 4R improved when CTVs were deﬁned using 
the protocol. Risks of lung toxicity, as deﬁned by the lung volumes 
treated to 20 Gy and 5 Gy, varied between the smallest and second 
largest routine CTVs. For the post-lobectomy case, the V20 (range) 
was 11.8-19.3% and a V5 of 33.8-57.9%. The corresponding V20 and 
V5 values were 1.5-2.1% and 31.6-39.7% for the post-pneumonectomy 
case. Both cardiac volumes receiving 45 Gy and spinal doses were 
similar for both CTVs.
Conclusions: The variations in PORT volumes generated by experi-
enced clinicians resulted in large differences in the risk of lung toxicity. 
Standardized target deﬁnitions are needed in order to optimize the 
survival beneﬁts from PORT, and the LungArt protocol may serve this 
purpose.
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Background: Standard stratiﬁcation criteria in studies evaluating 
patients (pts) with locally advanced NSCLC generally include gender, 
stage, & weight loss, occasionally age and histology. However, con-
temporary analyses of more recent trials in LA-NSCLC to determine if 
these factors are still prognostic have not been conducted. 
Materials and Methods: We evaluated the baseline demographics of 
two separate phase III trials: (1) RTOG 9410, a randomized phase III 
trial in good prognosis LA-NSCLC comparing sequential cisplatin-
based chemotherapy followed by RT (63 Gy) to concurrent chemother-
apy & either once daily RT (63Gy) or twice daily (BID) RT (69.6 Gy) 
(platinum dose in each arm was equivalent) & (2) RTOG 9801, a phase 
III trial evaluating induction chemotherapy with paclitaxel & carbopla-
tin followed by concurrent BID RT, weekly paclitaxel & carboplatin ± 
amifostine. We assessed the distribution of prognostic variables in each 
study, & then analyzed hazard ratios, conﬁdence intervals, & p values 
for each potential prognostic factor, including age, stage, N status, 
histology, gender, KPS, tumor location, and hemoglobin. We then as-
sembled risk models with multiple prognostic factors in combination.
Results: 824 evaluable pts were accrued to these 2 efforts: 585 to 
RTOG 9410; 239 to RTOG 9801. 82% were under 70; 56% had stage 
IIIB NSCLC, 37% had squamous histology. 64% were male. 19% had 
N0-1 disease, 53% N2, 27% N3. KPS was 90-100 in 75%. 22% had 
primary tumor location in the lower lobe or multiple lobes. Baseline 
median hemoglobin was 13.4; 17% had baseline hemoglobin under 12. 
At this point 110 patients (13% of total enrollment) remain alive; 10% 
of those enrolled on 9410 with a median follow-up of 6 yrs, & 22% of 
those on 9801 with a median follow-up of 3 yrs. In univariate analysis 
by Cox modeling, KPS (90-100 versus 70-80; p=0.0002) & N status 
(N0 vs N1 vs N2 vs N3, p=0.0048) were highly prognostic; gender 
(female vs male; p=0.0481) & lobar location (upper lobe versus lower 
or multilobe; p=0.0206) were borderline prognostic. Age (<70 vs. >70, 
p=0.28), stage (II/IIIA vs. IIIB, p=0.16), histology (non-squamous vs. 
squamous, p=0.085) & hemoglobin (<12 vs. < 12, p=0.62) were not 
prognostic. 
Age, stage, gender, N status (0, 1 vs 2, 3), KPS, histology, tumor loca-
tion & Hgb were dichotomized into 2 levels, one level corresponding 
with a worse prognosis, the other a better prognosis; pts were then 
grouped into three cohorts of combined poor prognosis factors 0, 1 vs 
2, 3 vs >3. The distribution and hazard ratios follow:
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Conclusions: Independently, KPS, tumor location, N status, & gender 
have proven prognostic in platinum-based RTOG trials. However, 
prognostic modeling in LA-NSCLC, in the setting of non-operative 
combined modality therapy, is best performed by assessing multiple 
risk factors simultaneously rather than 1 variable at a time. Our evi-
dence-based joint analysis improves our prognostic ability & consti-
tutes a more clear-headed approach toward therapeutic stratiﬁcation in 
the presence of multiple prognostic variables. Observations from this 
analysis will help determine future stratiﬁcations in RTOG trials. 
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Background: Our previous IPD meta-analyses of CT in locally ad-
vanced NSCLC suggested that adding sequential CT to radiotherapy 
improved survival (BMJ 1995;311:899) and that adding concomitant 
CT to radiotherapy could also improve survival (inconsistent results in 
sensitivity analyses) (Ann Oncol 2006;17:473). The NSCLC Collabora-
tive Group reports here the update of these meta-analyses.
Methods: Systematic searches for RCTs were followed by central 
collection, checking and re-analysis of updated IPD. Results from indi-
vidual trials were combined using the stratiﬁed (by trial) log-rank test 
to calculate pooled hazard ratios (HRs). Previously included old trials 
using deleterious long-term alkylating agents were excluded from the 
updated sequential CT analysis.
Results: 31 RCTs were eligible for the meta-analysis of sequential CT. 
IPD was received from 21 RCTs (3473 patients) and only survival HR 
from one RCT (366 patients, IPD soon available). The survival analysis 
was based on these 22 trials and 3839 patients (78% of all known 
randomised patients). This adds 5 trials (1471 patients) to the 1995 
analysis. Median follow-up was 6.9 years. Sixteen trials used induction 
CT±alternated or consolidation CT, 7 used consolidation±concomitant 
CT or alternated CT. One trial had one part on induction and another 
